MDCG 2019-16: the EU's guidance on cybersecurity for medical devices

Last updated:

Key takeaways

  • A note on sourcing: this guide is drawn from the publicly downloadable MDCG 2019-16 Rev.1 PDF published on the European Commission's health.ec.europa.eu site, cross-checked against the MDR and IVDR texts on EUR-Lex.
  • MDCG 2019-16 does not invent new cybersecurity law; it maps existing MDR/IVDR essential requirements onto practical guidance.
  • Chapter 4 covers what a manufacturer must document and disclose.
  • Chapter 5 extends the same cybersecurity lens into the post-market phase.

MDCG 2019-16, "Guidance on Cybersecurity for medical devices," is the EU's main interpretive guidance on how connected medical device manufacturers meet the cybersecurity essential requirements already written into MDR Annex I (Regulation (EU) 2017/745) and IVDR Annex I (Regulation (EU) 2017/746). First published in December 2019 and revised as Rev.1 in July 2020, it was endorsed by the Medical Device Coordination Group (MDCG) — Member State representatives chaired by the European Commission — but, as the document states of itself, it "is not a European Commission document" and carries no independent legal force; only the Court of Justice of the EU can bind interpretation of Union law. In practice, it is the reference manufacturers, notified bodies and consultants use to turn MDR/IVDR's high-level essential requirements into a workable pre-market and post-market cybersecurity programme.

A note on sourcing: this guide is drawn from the publicly downloadable MDCG 2019-16 Rev.1 PDF published on the European Commission's health.ec.europa.eu site, cross-checked against the MDR and IVDR texts on EUR-Lex. MDCG guidance is non-binding by its own terms — treat anything below as interpretive context, not a substitute for the regulations themselves or for legal advice.

Where the requirements actually come from

MDCG 2019-16 does not invent new cybersecurity law; it maps existing MDR/IVDR essential requirements onto practical guidance. Its own correspondence table lines up the relevant MDR Annex I sections against their IVDR Annex I equivalents:

Topic MDR Annex I IVDR Annex I
Risk management system / risk control measures 3 / 4 3 / 4
Development per state of the art, incl. information security, V&V 17.2 16.2
Minimum IT requirements (hardware, network, IT security) 17.4 16.4
Protection against unauthorised access 18.8 —
Minimum IT requirements disclosed in instructions for use 23.4(ab) 20.4.1(ah)

The clearest single clause is MDR Article 17.4 / IVDR Article 16.4, quoted directly in the guidance: manufacturers "shall set out minimum requirements concerning hardware, IT networks characteristics and IT security measures, including protection against unauthorised access, necessary to run the software as intended." MDCG 2019-16 spends most of its length explaining what satisfying that one clause looks like in practice.

Secure design and manufacture

Chapter 3 of the guidance sets out a "secure by design" expectation running through the device life cycle: a documented security risk management process (run alongside, not instead of, the device's ISO 14971 safety risk management file), the identification of security capabilities the device needs, a security risk assessment, and — distinctively — a security benefit-risk analysis that weighs a security control's side effects (for example, an authentication step that could delay emergency use) against the risk it mitigates. The guidance's minimum IT requirements section works through MDR 17.4/IVDR 16.4 clause by clause, giving a non-exhaustive, non-mandatory list of possible operating-environment controls — network segmentation, access management, anti-malware, patch management — that a manufacturer can draw on when defining what its device needs from its hosting environment, while making clear the manufacturer alone decides which of those controls actually apply to its own device and risk profile.

Documentation, instructions for use, and the MDS2 form

Chapter 4 covers what a manufacturer must document and disclose. Instructions for use must include the device's minimum IT/network/security requirements (the Article 23.4(ab)/20.4.1(ah) disclosure duty) in a form clear enough for an operator to actually configure a safe environment around the device. The guidance also points to the MDS2 (Manufacturer Disclosure Statement for Medical Device Security), describing it as "an industry-wide and globally accepted form" a manufacturer can use to convey the device's security information to purchasers and operators in a standard structure.

Post-market surveillance and vigilance

Chapter 5 extends the same cybersecurity lens into the post-market phase. A manufacturer's post-market surveillance (PMS) system under MDR Article 83 / IVDR Article 78 must actively collect and review cybersecurity-relevant field experience, not just safety complaints. For vigilance reporting under MDR Article 87 / IVDR Article 82, the guidance maps cybersecurity root causes onto existing IMDRF coding: device problem code A110502 ("Computer System Security Problem," further split into application security problems and unauthorized access) and incident root-cause code C1007 ("Software Security Vulnerability"). MDCG 2019-16's Annex II gives worked examples distinguishing a security incident from a reportable serious incident — ranging from malware on an external programmer for an implantable deep brain stimulator or pacemaker, to ransomware against a PACS system, to a legacy RDP vulnerability on an X-ray machine — explicitly flagged as illustrative rather than an exhaustive list of what to expect.

Standards referenced — with an explicit conformity disclaimer

Annex III lists standards the guidance considers relevant to cybersecurity, including EN ISO 14971 (safety risk management), IEC 62304 (software lifecycle), ISO/IEC 27001, ISO/IEC 80001-1 and IEC 81001-5-1, IEC 62443-4-1 and 62443-4-2, and IEC/TR 60601-4-5. The annex carries its own disclaimer, worth quoting in full: this section "is intended for information purposes only and does not provide any guidance that could be used for the purposes of meeting requirements" under MDR or IVDR, and the listed standards "cannot provide a presumption of conformity, unless they are harmonised under the aforementioned regulations and published in the Official Journal." Citing one of these standards in a technical file is evidence of a reasonable approach, not an automatic conformity shortcut the way a harmonised standard would be.

A workable starting point

  1. Treat it as interpretation, not lawMDCG 2019-16 explains how to read MDR/IVDR Annex I's cybersecurity clauses; the binding obligations are in the regulations themselves, and only harmonised standards published in the Official Journal carry a presumption of conformity.
  2. Run security risk management alongside, not inside, your safety risk fileThe guidance expects a security risk management process, a security benefit-risk analysis, and (per ANSI/AAMI SW96) a dedicated security risk management file that feeds back into the ISO 14971 safety file where risks overlap.
  3. Write the IT security disclosures into the instructions for use, not just the technical fileArticle 17.4/16.4's minimum IT requirements duty is also an Article 23.4(ab)/20.4.1(ah) disclosure duty — an operator needs to actually read what environment the device expects.
  4. Pre-map your vigilance process to IMDRF codes A110502 and C1007before an incident happens, so a genuine security-root-cause event is reported through the same Article 87/82 channel as any other serious incident, not handled as a separate, slower track.
  5. Check MDCG's live guidance list before citing a specific revisionThis guide covers Rev.1 (July 2020); confirm no newer MDCG 2019-16 revision has since been endorsed before citing a clause number in a submission.

SoftWSP's device and firmware security work can help build the risk assessment, SBOM and vulnerability-monitoring evidence an MDR/IVDR technical file's cybersecurity section expects: see Device & Firmware Security.

This guide summarises a publicly available MDCG guidance document and the MDR/IVDR texts on EUR-Lex; it is not a substitute for the regulations, the current MDCG guidance list, or legal advice. MDCG 2019-16 is explicitly non-binding and does not itself reflect an official European Commission position.

Sources

  1. European Commission / MDCG: MDCG 2019-16 Rev.1 — Guidance on Cybersecurity for medical devices (endorsed document, December 2019; Rev.1 July 2020)
  2. European Commission: Guidance — MDCG endorsed documents and other guidance (list page hosting MDCG 2019-16 and other MDCG guidance)
  3. EUR-Lex: Regulation (EU) 2017/745 on medical devices (MDR), Article 103 (Medical Device Coordination Group) and Annex I
  4. EUR-Lex: Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR)
  5. EUR-Lex: Directive (EU) 2022/2555 (NIS2), repealing Directive (EU) 2016/1148 cited in MDCG 2019-16 Chapter 6
  6. European Commission: Legal notice — reuse policy for Commission website content (Commission Decision of 12 December 2011; CC BY 4.0 default licence for EU-owned content)

Frequently asked questions

What is MDCG 2019-16, and is it legally binding?

MDCG 2019-16, "Guidance on Cybersecurity for medical devices," is a guidance document endorsed by the Medical Device Coordination Group (MDCG), the body established under Article 103 of Regulation (EU) 2017/745 (MDR) and composed of representatives of every EU Member State, chaired by a European Commission representative. It was first published in December 2019 and revised (Rev.1) in July 2020. The document itself states plainly that it "is not a European Commission document and it cannot be regarded as reflecting the official position of the European Commission," and that "any views expressed in this document are not legally binding and only the Court of Justice of the European Union can give binding interpretations of Union law." In practice, manufacturers and notified bodies treat it as the standard reference for how to interpret MDR/IVDR's cybersecurity essential requirements, even though it has no independent legal force of its own.

What does MDCG 2019-16 actually require manufacturers to do?

It does not create new legal requirements; it explains how to fulfil cybersecurity-relevant essential requirements already in MDR Annex I and IVDR Annex I — covering device performance, risk reduction, the risk management system, risk control measures, minimisation of foreseeable risks, interoperability, state-of-the-art development taking into account information security, minimum IT requirements, protection against unauthorised access, and the corresponding instructions-for-use disclosures. The guidance groups its recommendations into secure design and manufacture (Chapter 3), documentation and instructions for use (Chapter 4), and post-market surveillance and vigilance (Chapter 5).

How does MDCG 2019-16 relate to FDA's Section 524B rules and to IEC/ISO standards like 62304, 81001-5-1 and 62443-4-2?

MDCG 2019-16 and FDA's Section 524B premarket cybersecurity duties address the same underlying engineering work — secure design, risk management, documentation, vulnerability handling and post-market monitoring — under two separate legal systems that do not cross-reference each other; see our guide to [FDA premarket cybersecurity for medical devices](/guides/fda-premarket-cybersecurity-medical-devices/). MDCG 2019-16's own Annex III lists standards it considers relevant without endorsing any as sufficient for a presumption of conformity, including EN ISO 14971 (safety risk management), IEC 62304 (software lifecycle), ISO/IEC 27001, ISO/IEC 80001-1 and 80001-5-1, IEC 62443-4-1 and 62443-4-2, and IEC/TR 60601-4-5 — the same family of standards covered elsewhere on this site. The Annex III disclaimer is explicit: these standards "cannot provide a presumption of conformity, unless they are harmonised under" the MDR/IVDR and published in the Official Journal.

Has MDCG 2019-16 been updated since 2020, and does it reflect NIS2 or the Cyber Resilience Act?

No confirmed further revision beyond Rev.1 (July 2020) was found as of this guide's publication — check MDCG's own live list of endorsed guidance documents before relying on a specific edition. The document's Chapter 6 discussion of "other legislation" cites the original 2016 NIS Directive (Directive (EU) 2016/1148), which has since been repealed and replaced by the NIS2 Directive (Directive (EU) 2022/2555); see our guide to [NIS2](/guides/nis2-directive-explained/). MDCG 2019-16 predates both NIS2 and the EU Cyber Resilience Act (which in any case excludes medical devices already regulated under MDR/IVDR from its scope), so neither is discussed in the document's text.

In this cluster

MDCG 2019-16: the EU's guidance on cybersecurity for medical devices